Navigation Links
Marshall Edwards Adds $2 Million in Private Placement
Date:12/29/2011

ical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and expects final data from the trial in the second quarter of 2012. The second program is a family of mitochondrial inhibitors that includes lead candidate ME-344. The Company has completed the necessary pre-clinical animal toxicity studies to support submission of an Investigational New Drug (IND) application for ME-344 in the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rig
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- The escalation of new biological ... renewed emphasis on alternate delivery technologies. Alternate delivery ... of factors are converging to create both ... delivery device partners . These include new classes ... trend toward self-administration for chronic diseases, shifting patient ...
(Date:5/17/2013)... Inc. (NASDAQ: ATOS ), The Breast Health Company™, ... Financial Officer & General Counsel, will present at the Second ... in New York City at the ... scheduled to begin at 3:30 p.m. EDT and will be ... to www.atossagenetics.com . For more information and ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
(Date:5/19/2013)... (PRWEB) May 20, 2013 May is ... USA. Although located down under, Platypus Australia, the country's ... commemorated ‘Melanoma Monday’ on May 6th to kick off ... to parents. , With the staggering number of ... led to feverish research to find out what’s causing ...
(Date:5/19/2013)... ATS 2013, PHILADELPHIA ─ Gourmands and foodies everywhere have ... a little peppery zing to both sweet and savory ... shows purified components of the spicy root also may ... , The results of the study will be presented ... characterized by bronchoconstriction, a tightening of the bronchial tubes ...
(Date:5/19/2013)... Omaha, Nebraska is a city of diversity, economic ... of the lowest unemployment rates in the country. Forbes Magazine ... for Business and Careers and it consistently scores high on ... located in the nation and is a strong business leader ... of Editions TV are pleased to announce air ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... move forward in a federal litigation now underway in ... to a Case Management Order dated May 3rd, the ... the Bellwether Nominee Pool to eight cases rather than ... litigation is scheduled for Thursday, May 23rd. (In re: ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Grinding your ... just losing sleep, or annoying your spouse. At the ... by CNY Central (“Snoring and Teeth Grinding Could Be ... of teeth grinding can be hard to prevent. Apparently, ... Americans, and one of its symptoms is a habit ...
Breaking Medicine News(10 mins):Health News:Leading Children’s Sun Protection Swimwear Company Platypus Australia use Skin Cancer Awareness Month to Help Educate Parents 2Health News:Leading Children’s Sun Protection Swimwear Company Platypus Australia use Skin Cancer Awareness Month to Help Educate Parents 3Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Editions TV Announces May Air Dates for Omaha, Nebraska 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3
... relatively simple methods, an ultrasound investigation and a blood test ... can predict survival and future heart failure following acute coronary ... the University of Gothenburg, Sweden. Acute coronary syndromes, such ... common causes of emergency medical care and death in Sweden ...
... Elsevier, a world-leading publisher of scientific, technical, and medical ... of the first issue of Practical Radiation Oncology ... Radiation Oncology (ASTRO). Under the guidance of Editor-in-Chief ... aims to improve the quality of radiation oncology practice. ...
... Lake, N.Y. There is an ongoing battle in the ... -- a race between scientists working to develop a vaccine ... use plague as a weapon. "Governments remain concerned that ... could kill thousands," said Stephen Smiley, a leading plague researcher ...
... with human immunodeficiency virus (HIV) impaired results of ... infected patients dropping off the transplantation wait list. ... survival was not impacted following liver transplantation in ... single center studythe largest to dateare published in ...
... 2011 Sustained exposure to loud workplace noise may affect ... to a new study by Ben-Gurion University of the Negev ... , the study compared the sleep quality of individuals at ... some without. Workers with hearing loss had ...
... behavior is similar to that of a person with brain ... forms of treatment," said Dr. Simone Shamay-Tsoory, who conducted the ... just like patients who have suffered frontal head injury. This ... of Haifa. "Our findings show that people who have psychopathic ...
Cached Medicine News:Health News:Ultrasound and a blood test can increase survival after myocardial infarction 2Health News:New discovery could lead to vaccines for plague and bacterial pneumonias 2Health News:Patients infected with HIV have higher drop-out rate for liver transplantation 2Health News:A psychopath lacks empathy just like a person with frontal head injury 2
... motility testing simpler than ever ... up in seconds and protect ... sensor circumferential, Air-Charged Catheters improve ... For advanced performance made easy, ...
... single-use products to promote safety for your ... catheter reduces cross-contamination and helps protect your ... because cleaning is eliminated, you have more ... water perfused manometric catheters for esophageal, anorectal ...
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Medicine Products: